Ilaprazole: Distinctive Pharmacokinetic and Pharmacodynamic Properties Among Proton Pump Inhibitors

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Gastroenterology & Endoscopy

• Publication date

  2025-04-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.gande.2025.04.001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori

  2020cited by this paper
• Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis

  2018cited by this paper
• Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections

  2017cited by this paper
• High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea

  2016cited by this paper
• A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis

  2016cited by this paper
• Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses

  2016cited by this paper
• Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects

  2016cited by this paper
• Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China

  2016cited by this paper
• Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

  2016cited by this paper
• Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.

  2015cited by this paper
• Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis.

  2014cited by this paper
• The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open‐label crossover study

  2014cited by this paper
• Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection

  2014cited by this paper
• The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

  2013cited by this paper
• Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan

  2013cited by this paper
• [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].

  2012cited by this paper
• Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole

  2012cited by this paper
• The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease

  2012cited by this paper
• Acid inhibition effect of ilaprazole on Helicobacter pylori‐negative healthy volunteers: An open randomized cross‐over study

  2012cited by this paper
• A New PPI, Ilaprazole Compared With Omeprazole in the Treatment of Duodenal Ulcer: A Randomized Double-Blind Multicenter Trial

  2011cited by this paper
• Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments.

  2010cited by this paper
• Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

  2010cited by this paper
• Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication

  2010cited by this paper
• Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers

  2009cited by this paper
• Might the Use of Acid-Suppressive Medications Predispose to the Development of Eosinophilic Esophagitis?

  2009cited by this paper
• [Prevalence and incidence of dementia in Germany--a study based on data from the public sick funds in 2002].

  2009cited by this paper
• Proton pump inhibitors and clopidogrel: putting the interaction in perspective.

  2009cited by this paper
• Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites

  2009cited by this paper
• Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori.

  2009cited by this paper
• Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.

  2008cited by this paper
• Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

  2008cited by this paper
• Proton Pump Inhibitors

  2008cited by this paper
• Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.

  2008cited by this paper
• Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

  2008cited by this paper
• Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations

  2008cited by this paper
• Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  2008cited by this paper
• Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.

  2007cited by this paper
• Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure

  2006cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• Review article: the clinical pharmacology of proton pump inhibitors

  2006cited by this paper
• 2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study

  2006cited by this paper
• Acid Suppression Therapy: Where Do We Go from Here?

  2006cited by this paper
• Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.

  2006cited by this paper
• Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

  2005cited by this paper
• Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

  2005cited by this paper
• Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.

  2005cited by this paper
• CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.

  2005cited by this paper
• Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

  2005cited by this paper
• Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes

  2004cited by this paper
• Effects of lansoprazole on pharmacokinetics and metabolism of theophylline

  2004cited by this paper
• Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications

  2004cited by this paper
• Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects

  2004cited by this paper
• Lansoprazole—Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism

  2004cited by this paper
• Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

  2004cited by this paper
• Propranolol steady-state pharmacokinetics are unaltered by omeprazole

  2004cited by this paper
• Gastric acid‐suppressive therapy and community‐acquired respiratory infections

  2003cited by this paper
• Esomeprazole — enhanced bio‐availability, specificity for the proton pump and inhibition of acid secretion

  2003cited by this paper
• Validity of the General Practice Research Database

  2003cited by this paper
• Physiology of the Parietal Cell and Therapeutic Implications

  2003cited by this paper
• The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.

  2003cited by this paper
• The genetic determinants of the CYP3A5 polymorphism.

  2001cited by this paper
• Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19

  2001cited by this paper
• Effects of IY-81149, a Newly Developed Proton Pump Inhibitor, on Gastric Acid Secretion in vitro and in vivo

  2001cited by this paper
• Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole

  2001cited by this paper
• Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation.

  2000cited by this paper
• Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.

  2000cited by this paper
• Comparison of IY81149 with omeprazole in rat reflux oesophagitis.

  2000cited by this paper
• A comparative pharmacodynamic study of IY‐81149 versus omeprazole in patients with gastroesophageal reflux disease

  2000cited by this paper
• Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

  1999cited by this paper
• Lack of Pharmacokinetic Interaction between Oral Pantoprazole and Cisapride in Healthy Adults

  1999cited by this paper
• Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry

  1999cited by this paper
• Use of the UK General Practice Research Database for pharmacoepidemiology.

  1998cited by this paper
• Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S‐mephenytoin

  1997cited by this paper
• Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.

  1997cited by this paper
• Overview of enzymes of drug metabolism

  1996cited by this paper
• Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.

  1995cited by this paper
• Interethnic difference in omeprazole's inhibition of diazepam metabolism

  1995cited by this paper
• Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S‐mephenytoin 4′‐hydroxylation

  1995cited by this paper
• Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation.

  1993cited by this paper
• Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

  1992cited by this paper
• Omeprazole-cyclosporin interaction.

  1991cited by this paper
• Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

  1991cited by this paper
• Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.

  1991cited by this paper
• Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase. The effect of the enantiomers of omeprazole on gastric glands.

  1990cited by this paper
• Inhibitory effect of omeprazole on the metabolism of midazolam in vitro.

  1990cited by this paper
• Omeprazole in the management of refractory duodenal ulcer.

  1989cited by this paper
• Oral phenytoin pharmacokinetics during omeprazole therapy.

  1987cited by this paper
• Mechanisms for the incorporation of proteins in membranes and organelles

  1982cited by this paper
• Phenobarbital induction of NADPH-cytochrome c (P-450) oxidoreductase messenger ribonucleic acid.

  1980cited by this paper

• Exploring Ilaprazole-CYP2C19 interaction: A computational study on metabolic stability and drug-drug interaction potential

  2025cites this paper